tradingkey.logo

Bristol Myers Squibb Announces Topline Results From Phase 3 Arise Trial Evaluating Cobenfy As An Adjunctive Treatment To Atypical Antipsychotics In Adults With Schizophrenia

ReutersApr 22, 2025 8:54 PM

- Bristol-Myers Squibb Co BMY.N:

  • BRISTOL MYERS SQUIBB ANNOUNCES TOPLINE RESULTS FROM PHASE 3 ARISE TRIAL EVALUATING COBENFY (XANOMELINE AND TROSPIUM CHLORIDE) AS AN ADJUNCTIVE TREATMENT TO ATYPICAL ANTIPSYCHOTICS IN ADULTS WITH SCHIZOPHRENIA

  • BRISTOL-MYERS SQUIBB CO - COBENFY DID NOT REACH STATISTICAL SIGNIFICANCE IN PHASE 3 TRIAL

  • BRISTOL-MYERS SQUIBB CO - COBENFY SAFETY AND TOLERABILITY CONSISTENT WITH PREVIOUS TRIALS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI